Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate

2008 ◽  
Vol 47 (7) ◽  
pp. 565-572 ◽  
Author(s):  
Olaf Bettendorf ◽  
Hartmut Schmidt ◽  
Annette Staebler ◽  
Rainer Grobholz ◽  
Achim Heinecke ◽  
...  

2004 ◽  
Vol 39 (6) ◽  
pp. 594-595 ◽  
Author(s):  
Yasuhiro Komuro ◽  
Toshiaki Watanabe ◽  
Takamitsu Kanazawa ◽  
Tomohiro Tada ◽  
Kazuhiko Fukatsu ◽  
...  


2021 ◽  
Vol 54 (2) ◽  
pp. 57-64
Author(s):  
Okuto Koguchi ◽  
Haruna Nishimaki ◽  
Yoko Nakanishi ◽  
Hiroko Kobayashi ◽  
Sumie Ohni ◽  
...  


Author(s):  
José Eleutério Jr ◽  
Thiago Lima ◽  
Maria Cunha ◽  
Diane Cavalcante ◽  
Angélica Silva

Objective To evaluate the diagnostic utility of the p16ink4a protein expression as a marker for adenocarcinoma of the cervix. Methods In a cross-sectional study, p16ink4a expression was evaluated in 30 cervical biopsies from patients diagnosed with invasive adenocarcinoma from 2 reference clinics in Brazil, and compared with 18 biopsies of endocervical polyps (control cases). The performance of the tests for p16ink4a was evaluated using a conventional contingency table, and the Kappa (κ) index was used to evaluate the agreement of the marker with the tissue diagnosis. Results In total, 66% of the invasive adenocarcinoma cases were positive for p16ink4a. All of the adenomatous polyps cases used as negative controls were shown to be negative for p16ink4a. The marker showed a high sensitivity and a high negative predictive value. The Kappa index was good for p16ink4a (κ = 0.6). Conclusion Considering the strong association between the p16ink4a marker and the cervical adenocarcinoma, its use represents an important tool for reducing incorrect diagnoses of adenocarcinoma and thereby avoiding overtreatment.





2018 ◽  
Vol 142 (8) ◽  
pp. 938-946 ◽  
Author(s):  
Thomas K. Lee ◽  
Jae Y. Ro

Context.— The presence of cribriform glands/ducts in the prostate can pose a diagnostic challenge. Cribriform glands/ducts include a spectrum of lesions, from benign to malignant, with vastly different clinical, prognostic, and treatment implications. Objective.— To highlight the diagnostic features of several entities with a common theme of cribriform architecture. We emphasize the importance of distinguishing among benign entities such as cribriform changes and premalignant to malignant entities such as high-grade prostatic intraepithelial neoplasia, atypical intraductal cribriform proliferation, intraductal carcinoma of the prostate, and invasive adenocarcinoma (acinar and ductal types). The diagnostic criteria, differential diagnosis, and clinical implications of these cribriform lesions are discussed. Data Sources.— Literature review of pertinent publications in PubMed up to calendar year 2017. Photomicrographs obtained from cases at the University of California at Irvine and authors' collections. Conclusions.— Although relatively uncommon compared with small acinar lesions (microacinar carcinoma and small gland carcinoma mimickers), large cribriform lesions are increasingly recognized and have become clinically and pathologically important. The spectrum of cribriform lesions includes benign, premalignant, and malignant lesions, and differentiating them can often be subtle and difficult. Intraductal carcinoma of the prostate in particular is independently associated with worse prognosis, and its presence in isolation should prompt definitive treatment. Patients with atypical intraductal cribriform proliferation, intraductal carcinoma of the prostate, or even focal cribriform pattern of invasive adenocarcinoma in biopsies would not be ideal candidates for active surveillance because of the high risk of adverse pathologic findings associated with these entities.



2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 58.1-58
Author(s):  
P. Kohlberger ◽  
C. Beneder ◽  
R. Horvat ◽  
S. Leodolter ◽  
G. Breitenecker


2012 ◽  
Vol 109 (30) ◽  
pp. 12046-12051 ◽  
Author(s):  
Anette Hübner ◽  
David J. Mulholland ◽  
Claire L. Standen ◽  
Maria Karasarides ◽  
Julie Cavanagh-Kyros ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document